Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone (2005-2006 Formulation)
NCT00258830Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2005
- Primary completion
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Fluzone Trivalent in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions and Geometric Mean Titers of Hemagglutination Antibodies at 21 days. Started Sep 2005; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00258830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258830.